{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T16:19:07Z","timestamp":1681834747476},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Both older and newer cell therapies have demonstrated impressive responses in otherwise poor-prognosis lymphomas. Consequently, cellular therapy now plays a major role in the management of many non-Hodgkin lymphomas. In this article, we examine the role of chimeric antigen receptor (CAR) T cells, allogeneic stem cell transplantation, and virus-directed T cells for treatment of lymphomas. We review the current indications for CAR T cells and discuss our clinical approach to selecting and treating patients with aggressive B-cell lymphomas to receive CD19-directed CAR T cells. In addition, we highlight newer cell therapies and provide an overview of promising future approaches that have the potential to transform immunotherapy with cells to treat lymphomas.<\/jats:p>","DOI":"10.1182\/hematology.2020000174","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T04:43:12Z","timestamp":1607143392000},"page":"590-597","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy with cells (article not eligible for CME credit)"],"prefix":"10.1182","volume":"2020","author":[{"given":"Elise A.","family":"Chong","sequence":"first","affiliation":[{"name":"Lymphoma Program and Cell Therapy and Transplant Program, Hematology-Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[{"name":"Lymphoma Program and Cell Therapy and Transplant Program, Hematology-Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"16","key":"2020121621272687000_B1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588.]","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2020121621272687000_B2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00262-014-1568-1","article-title":"Engineered T cells for cancer therapy","volume":"63","author":"June","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"26","key":"2020121621272687000_B3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020121621272687000_B4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020121621272687000_B5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"S2","key":"2020121621272687000_B6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/hon.118_2630","article-title":"Correlative analyses of cytokine release syndrome and neurological events in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients","volume":"37","author":"Bachanova","year":"2019","journal-title":"Hematol Oncol"},{"issue":"10","key":"2020121621272687000_B7","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"issue":"S2","key":"2020121621272687000_B8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/hon.96_2629","article-title":"CD19-directed CAR T cell therapy (CTL019) for relapsed\/refractory diffuse large B-cell and follicular lymphomas: four year outcomes","volume":"37","author":"Chong","year":"2019","journal-title":"Hematol Oncol"},{"key":"2020121621272687000_B9","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy [published online ahead of print 6 October 2020]","author":"Cappell","journal-title":"J Clin Oncol"},{"issue":"27","key":"2020121621272687000_B10","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10254","key":"2020121621272687000_B11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"2020121621272687000_B12","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2020121621272687000_B13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2020121621272687000_B14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2020121621272687000_B15","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl_1","key":"2020121621272687000_B16","article-title":"Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium [abstract]","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2020121621272687000_B17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2020121621272687000_B18","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2020121621272687000_B19","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2020121621272687000_B20","article-title":"Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory large B cell lymphoma [abstract]","volume":"134","author":"Topp","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621272687000_B21","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL) [abstract]","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2020121621272687000_B22","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2020121621272687000_B23","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"2020121621272687000_B24","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"303","key":"2020121621272687000_B25","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"suppl 1","key":"2020121621272687000_B26","article-title":"Rapid undetectable MRD (uMRD) responses in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) treated with lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T cell product: updated results from transcend cll 004, a phase 1\/2 study including patients with high-risk disease previously treated with ibrutinib [abstract]","volume":"134","author":"Siddiqi","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621272687000_B27","article-title":"Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate [abstract]","volume":"132","author":"Gill","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2020121621272687000_B28","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2020121621272687000_B29","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2020121621272687000_B30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","article-title":"Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL) [abstract]","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020121621272687000_B31","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl_1","key":"2020121621272687000_B32","article-title":"Long-term outcomes of subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disorder (EBV+PTLD) following solid organ (SOT) or allogeneic hematopoietic cell transplants (HCT) treated with tabelecleucel on an expanded access program [abstract]","volume":"134","author":"Prockop","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020121621272687000_B33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"issue":"14","key":"2020121621272687000_B34","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2010.32.8419","article-title":"Allogeneic transplantation for lymphoma","volume":"29","author":"Chakraverty","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020121621272687000_B35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"issue":"20","key":"2020121621272687000_B36","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2020121621272687000_B37","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","article-title":"Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients","volume":"22","author":"Fenske","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020121621272687000_B38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"2020121621272687000_B39","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020121621272687000_B40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2018-01-791335","article-title":"Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas","volume":"132","author":"Schmitz","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621272687000_B41","article-title":"Donor lymphocyte infusions for the treatment of relapsed non-Hodgkin lymphoma following allogeneic stem cell transplantation: a LWP-EBMT study [abstract]","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020121621272687000_B42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"2020121621272687000_B43","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"2020121621272687000_B44","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1002\/ajh.25399","article-title":"Allogeneic CAR T cell therapies for leukemia","volume":"94","author":"Qasim","year":"2019","journal-title":"Am J Hematol"},{"issue":"374","key":"2020121621272687000_B45","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"issue":"6","key":"2020121621272687000_B46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/590\/1795101\/hem2020000174c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/590\/1795101\/hem2020000174c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:19:21Z","timestamp":1608315561000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/590\/474334\/Immunotherapy-with-cells-article-not-eligible-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000174","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}